YB-1 protein correlates with high-risk tumor characteristics and response to high dose chemotherapy in breast cancer.

被引：0
|
作者：
Gluz, O.
Harbeck, N.
Kates, R. E.
Schmitt, M.
Mengele, K.
Royer, H-D
Eckstein, N.
Svjetlana, M.
Ting, E.
Poremba, C.
Nitz, U.
Diallo-Danebrock, R.
机构：
[1] Univ Dusseldorf, D-4000 Dusseldorf, Germany
[2] Tech Univ, Munich, Germany
[3] Caesar Inst, Bonn, Germany
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [31] High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer
    Rodenhuis, S
    Bontenbal, M
    Beex, LVAM
    Wagstaff, J
    Richel, DJ
    Nooij, MA
    Voest, EE
    Hupperets, P
    van Tinteren, H
    Peterse, HL
    TenVergert, EM
    de Vries, EGE
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (01): : 7 - 16
  • [32] High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer
    Martin S. Tallman
    William J. Gradishar
    Cancer Chemotherapy and Pharmacology, 1998, 42 : S60 - S67
  • [33] High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?
    Nieto, Yago
    Shpall, Elizabeth J.
    CURRENT OPINION IN ONCOLOGY, 2009, 21 (02) : 150 - 157
  • [34] Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer
    Fields, KK
    Elfenbein, GJ
    Perkins, JB
    Ballester, OF
    Goldstein, SC
    Heimenz, JW
    Saez, RA
    Sullivan, DM
    Partyka, JS
    Kronish, LA
    SEMINARS IN ONCOLOGY, 1998, 25 (02) : 1 - 6
  • [35] Sequential high-dose chemotherapy with peripheral blood stem cell (PBSC) support as adjuvant therapy for patients with high-risk breast cancer.
    Hohaus, S
    Wallwiener, D
    Schneeweiss, A
    Egerer, G
    Martin, S
    Abdallah, A
    Goldschmidt, H
    Fersis, N
    Bastert, G
    Haas, R
    BONE MARROW TRANSPLANTATION, 1998, 22 : S93 - S94
  • [36] Adjuvant chemotherapy for high-risk operable breast cancer
    Buzdar, Aman U.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1642 - 1644
  • [37] ADJUVANT CHEMOTHERAPY IN HIGH-RISK STAGE II COLON CANCER.
    Lightner, A.
    Glyn, T.
    Parker, M.
    Tse, C.
    Abdelsattar, Z.
    Larson, D.
    Mathis, K.
    DISEASES OF THE COLON & RECTUM, 2016, 59 (05) : E293 - E293
  • [38] Factors influencing pathological complete response and tumor regression in neoadjuvant radiotherapy and chemotherapy for high-risk breast cancer
    Haussmann, Jan
    Budach, Wilfried
    Nestle-Kraemling, Carolin
    Wollandt, Sylvia
    Jazmati, Danny
    Tamaskovics, Balint
    Corradini, Stefanie
    Boelke, Edwin
    Haussmann, Alexander
    Audretsch, Werner
    Matuschek, Christiane
    RADIATION ONCOLOGY, 2024, 19 (01)
  • [39] YB-1 expression (mRNA and protein) in sporadic breast cancer
    Macpherson, N
    Nelson, C
    Huntsman, D
    Burgess, A
    Zeznik, J
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S53 - S53
  • [40] Predictive value of ectopic HORMAD1 tumor expression for high-dose platinum-based chemotherapy benefit in patients with high-risk HER2-negative breast cancer.
    De Boo, Leonora
    Quist, Jelmar
    Opdam, Mark
    Jozwiak, Katarzyna
    Gazinska, Patrycja
    Peters, Dennis
    Horlings, Hugo M.
    Steenbruggen, Tessa Gerjanne
    Steggink, Lars C.
    De Vries, Elisabeth
    Sonke, Gabe S.
    Gietema, Jourik A.
    Tutt, Andrew
    Kok, Marleen
    Grigoriadis, Anita
    Linn, Sabine C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345